Being open and transparent

We believe in maintaining high standards in how we promote our medicines, and in being transparent in how we work

We are committed to sharing details of our relationships with patient organisations, healthcare professionals and relevant healthcare decision-makers; as well as details of all donations and grants provided to institutions, organisations or associations that are composed of healthcare professionals and/or that provide healthcare or conduct research.

Support for healthcare professionals and healthcare organisations is published annually on the Association of the British Pharmaceutical Industry (ABPI) central platform on 30th June of the following year.

Patient organisations and patient advocacy

Because we believe in the value of our relationships with patient organisations, we work hard to develop a deeper understanding of patient needs and to integrate such insights throughout our organisation. In this way, we create transparent partnerships that are central to our work of supporting patients and their caregivers on the journey to improved health and happy lives. 

Teva Guiding Principles for Patient Organisation Engagement:

Ethical Conduct & Integrity

Teva personnel are expected to maintain the highest standards of integrity in their relations with patient organisations.

Transparency

Teva will be open and transparent regarding relationships with patient organisations.

Teva will publicly disclose financial support and significant non-financial support provided to patient organisations. Further, patient organisations may publish Teva’s support of their programs as they deem appropriate. Teva’s global policy on patient organisation engagement is available to patient groups.

Mutual Benefit

Teva’s support of patient organisations is focused on improving the welfare of patients, families and caregivers. Any activity undertaken with patient organisations must clearly demonstrate benefit to the patients whose interests the patient groups represent.

Successful partnerships between patient organisations and Teva must provide mutual benefit to both organisations. Therefore, Teva will seek to build mutually beneficial relationships with patient organisations in areas where there is alignment around objectives and priorities.

Independence

A patient organisation in partnership with Teva must not have its independence compromised, nor should it be perceived to be compromised, and patient organisations retain the right to publicly object to the positions of the company.

Compliance

Every interaction between company personnel (and its representatives) and patient organisations will comply with all government rules, regulations and guidelines, as well as with all applicable Teva policies.

Non-Promotion

Teva must not use interactions and relationships with patient organisations to promote its products or increase commercial awareness of its products, except in countries that allow Direct to Consumer Advertising, and only when done in compliance with all applicable laws and Teva policies governing product promotion.

Contributions to patient organisations

Teva’s contributions to patient organisations last year, to support these organisations in delivering their respective goals and objectives, are published on our corporate website here.

This report will be updated annually.

Disclosure of patient organisation support

2020 disclosures

Organisation Registration
number
Website Details Amount

The Migraine Trust

1081300  Click here To support the organisation’s charitable objectives £3,727

The Migraine Trust

1081300  Click here Sponsorship of 2020 MTIS virtual congress (€70,000) £62,005

Leading a responsible business

We ensure all activities are carried out ethically and transparently

Discover more

Contributing to healthy communities

We recognize our responsibility to help address pressing healthcare challenges

Learn more

Environmental, Social & Governance Report (ESG)

We align our corporate resources and expertise with relevant areas of global health and social need

Learn more
Date of preparation: June 2022
Reference: COB-GB-NP-00048